- Home
- PLMK vs NBTX Comparison
PLMK vs NBTX Comparison
Compare PLMK & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLMK
- NBTX
- Stock Information
- Founded
- PLMK 2024
- NBTX 2003
- Country
- PLMK United States
- NBTX France
- Employees
- PLMK N/A
- NBTX N/A
- Industry
- PLMK
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- PLMK
- NBTX Health Care
- Exchange
- PLMK NYSE
- NBTX Nasdaq
- Market Cap
- PLMK 241.7M
- NBTX 211.9M
- IPO Year
- PLMK 2025
- NBTX 2020
- Fundamental
- Price
- PLMK $10.25
- NBTX $5.15
- Analyst Decision
- PLMK
- NBTX Strong Buy
- Analyst Count
- PLMK 0
- NBTX 1
- Target Price
- PLMK N/A
- NBTX $8.00
- AVG Volume (30 Days)
- PLMK 46.6K
- NBTX 6.5K
- Earning Date
- PLMK 01-01-0001
- NBTX 04-02-2025
- Dividend Yield
- PLMK N/A
- NBTX N/A
- EPS Growth
- PLMK N/A
- NBTX N/A
- EPS
- PLMK N/A
- NBTX N/A
- Revenue
- PLMK N/A
- NBTX N/A
- Revenue This Year
- PLMK N/A
- NBTX N/A
- Revenue Next Year
- PLMK N/A
- NBTX $221.06
- P/E Ratio
- PLMK N/A
- NBTX N/A
- Revenue Growth
- PLMK N/A
- NBTX N/A
- 52 Week Low
- PLMK $9.94
- NBTX $2.76
- 52 Week High
- PLMK $10.28
- NBTX $6.00
- Technical
- Relative Strength Index (RSI)
- PLMK N/A
- NBTX 52.43
- Support Level
- PLMK N/A
- NBTX $4.57
- Resistance Level
- PLMK N/A
- NBTX $5.00
- Average True Range (ATR)
- PLMK 0.00
- NBTX 0.25
- MACD
- PLMK 0.00
- NBTX -0.06
- Stochastic Oscillator
- PLMK 0.00
- NBTX 24.44
About PLMK PLUM ACQUISITION CORP IV
Plum Acquisition Corp IV is a blank check company.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.